Oxford Ovarian Cancer Predict Chemotherapy Response 01 (OXO-PCR-01)

University of Oxford logo

University of Oxford

Status

Unknown

Conditions

Ovarian Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT01770535
OXO-PCR-01

Details and patient eligibility

About

The purpose of the study is to understand why there are differences between individuals in the way they respond to paclitaxel chemotherapy.

Full description

While paclitaxel is very effective in killing cancer cells in a proportion of patients, some patients don't respond to this treatment. As with any chemotherapy, paclitaxel is associated with unpleasant side effects. We are doing this study to try and understand what is happening in cancer cells in different individuals after paclitaxel treatment that make them respond differently to the same treatment. We hope that this study will enable us to develop a method to identify women who are suitable for this form of treatment. We also want to understand why some cancer cells don't get killed with paclitaxel. This information will help us to select treatment to suit an individual patient, and thus improve the outcome of treatment and avoid giving treatment that will not benefit the patient.

Enrollment

35 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female ≥ 18 years of age
  • Newly diagnosed and histology confirmed primary high grade serous ovarian cancer, high grade serous fallopian tube cancer and primary peritoneal carcinoma.
  • Radiological and laparoscopic confirmation of FIGO stage 3C or 4 ovarian cancer.
  • Radiological evidence of omental or peritoneal deposits that are accessible for radiology-guided biopsy.
  • At least one lesion on CT scan measuring at least 2 cm in maximum diameter performed in the past 31 days. Slightly older scans may be accepted at the discretion of the CI providing the results are considered to remain clinically relevant.
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
  • Life expectancy of at least 6 months.
  • The patient is willing and able to provide written informed consent and comply with the protocol for the duration of the study, and scheduled visits and examinations.
  • Acceptable haematological and biochemical indices

Exclusion criteria

Trial contacts and locations

1

Loading...

Central trial contact

Ahmed A Ahmed

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems